TNBC is the most aggressive form of BC molecular subtypes. MBC is a rare form of BC that is usually TN. This study compares MBC (n [ 46) versus TNBC (508). The study concludes that MBC is more aggressive than TNBC. The study also provides a review of the literature that had similar approach. Background: We aimed to describe our experience with metaplastic breast carcinoma (MBC), evaluate its clinical outcome compared with triple-negative breast cancer (TNBC), and provide a through and comprehensive review of the literature to date. Materials and Methods: We reviewed MBC cases (n ¼ 46) from our institution. The following variables were recorded: tumor histologic subtype, Nottingham grade, tumor size, lymph node status, Tumor, Node, Metastases stage, biomarkers profile, patient's age and race, therapy modality (chemotherapy and radiation), and survival (disease-free survival [DFS] and overall survival [OS]). The clinical and pathological data for TNBC (n ¼ 508) cases were extracted from the breast cancer database. To compare the survival between MBC and TNBC, a subgroup of MBC cases (n ¼ 40) were matched with TNBC cases (n ¼ 40) on the basis of known prognostic confounders. Results: There were 17 of 46 (37%) cases with mesenchymal differentiation, 12 (26.1%) squamous cell carcinoma, 14 (30.4%) spindle cell carcinoma, and 3 (6.5%) mixed type. MBC presented at a more advanced stage than TNBC (P ¼ .014) and was more likely to recur (34% vs. 15.5%; P ¼ .004). More MBC patients died from disease than TNBC (29% vs. 16%; P ¼ .05). In the multivariate analysis, MBC had approximately twice the risk of local recurrence than TNBC (95% confidence interval, 1.01-3.83; P ¼ .05). MBC patients had worse DFS and OS than the matched TNBC patients (P < .001 and P ¼ .033, respectively). A review of the literature comparing MBC versus TNBC is presented. Conclusion: Our results suggest that MBC is clinically more aggressive than TNBC. Further studies might help delineate the differences between these 2 entities.
Introduction
Metaplastic breast cancer (MBC) is a rare and morphologically diverse group of tumors in which a variable proportion or the entire tumor is composed of nonglandular epithelium or mesenchymal cells. The 2011 World Health Organization (WHO) Working Group recognizes the following 5 subtypes: squamous cell carcinoma (SCC), MBC with mesenchymal differentiation, low grade adenosquamous carcinoma, spindle cell carcinoma, and fibromatosis-like metaplastic carcinoma. MBC accounts for approximately 0.2% to 5% of all breast cancer (BC). However, the prevalence varies to a large extent, because of the different definitions adopted by different authors. Pure metaplastic carcinoma has been reported to account for approximately 1% of all BC. In this study we adopted the criteria set by the WHO. 1 Metaplastic breast carcinomas present clinical features and age distribution similar to estrogen receptor (ER)-negative (ER À ) invasive carcinoma of no special type (IC-NST). 2, 3 A relatively consistent observation across many studies suggests that MBC tends to present with negative biomarkers (ER, progesterone receptor [PR] , and HER2). [4] [5] [6] [7] This has often led to its generalization with triple-negative BC (TNBC), which is a separate and distinct category of BC with different clinical behavior and treatment. Although most MBC have a triple-negative phenotype, anecdotally, the clinical outcomes seem different from TNBC. Nevertheless, few studies have compared the 2 entities side by side and the existing literature might overlook the differences in these 2 groups, largely in part because of small numbers and the inclusion of the favorable subtypes. 4, [8] [9] [10] [11] [12] [13] [14] [15] In our experience the clinical outcome seems to be worse than TNBC. Although some studies agree with this observation, 4, 9, 11, 12 other studies showed that there was no significant difference between these 2 subgroups. 7, 8, 10, 15 One of the issues in these previously published studies is how close the cases (MBC vs. TNBC) were matched. Therefore, in this study we aimed to carefully match these 2 groups in terms of patient age, Nottingham grade, tumor stage, and therapy modality including chemotherapy (CT) and radiation therapy (RT) with relatively long follow-up time. Then, we compared the diseasefree survival (DFS) and overall survival (OS).
Material and Methods
The institutional review board approved this retrospective study (BDR 040413).
Metaplastic Breast Carcinoma Cases
A retrospective review of a prospectively collected database was performed for MBC at Roswell Park Cancer Institute from 1992 to 2013, including all cases of MBC diagnosed between 1992 and 2013. This resulted in 81 cases that were then rereviewed jointly by 2 pathologists (T.K., D.E.) according to the 2011 WHO classification. 1 The hematoxylin and eosin stained slides were reviewed (1 to 25 slides per case with a median of 9 slides per case) and included if both of the following criteria were met: (1) the tumor had to have a component of invasive carcinoma or ductal carcinoma in situ with at least a 10% metaplastic component; and (2) when the tumor was pure sarcomatoid, it had to have at least 1 epithelial marker expression according to immunohistochemistry analysis (pancytokeratin, cytokeratin 5/6, high molecular weight cytokeratin, and/or p63).
The percentage of each metaplastic component (mesenchymal differentiation, SCC, spindle cell) and the nonmetaplastic component was estimated. The nonmetaplastic components were described as IC-NST and/or lobular. The case was considered metaplastic when the metaplastic component comprised > 10% of the tumor cells. The case was considered mixed metaplastic type when at least 2 metaplastic components were recognized, each comprising at least 10% of the tumor.
The following clinicopathologic data were recorded: patient's age, race, therapy modality (adjuvant, neoadjuvant; CT and RT), tumor size, lymph node status, American Joint Committee on Cancer (AJCC) Tumor, Node, Metastases (TNM) stage, biomarkers profile (ER, PR, and HER2), and survival data including DFS and OS.
Triple Negative BC Cases
All TNBC cases were retrieved from the prospectively maintained BC database in the same time frame. The inclusion criteria were: (1) ER À /PR À /HER2 À ; (2) tumor size larger than 1 mm; (3) not a metaplastic carcinoma; and (4) clinical, pathologic, and treatment data were available. The search yielded 508 cases. The clinical data including patient age, AJCC TNM stage, therapy modality (adjuvant, neoadjuvant, CT, RT), and survival data including DFS and OS were extracted from the database. For the TNBC matched cases (n ¼ 40) with the MBC cases, the slides were reviewed confirming the pathology diagnosis.
Statistical Analysis
The clinicopathologic factors were compared between selected cases of MBC and TNBC subtypes. Fisher exact test was used for categorical variables whereas Wilcoxon nonparametric test was used for continuous variables. All comparisons were 2-sided and a P value of .05 was considered significant. Univariate Cox proportional hazard analysis was performed to assess the risk of breast tumor recurrence and mortality relative to the clinicopathologic factors in BC cases. The significant clinicopathologic factors in the univariate analysis were then included in the multivariate analysis.
The cumulative survival differences for MBC and TNBC cases were assessed using the log rank method. Case matching was used to exclude the confounding factors in survival analysis. We included only the MBC cases with complete survival data (n ¼ 40) and matched them with the TNBC group. The matching included patient age using 50 years as the cutoff, as well as pathology stage (I, II, and III), Nottingham grade (1, 2, 3), therapy type (adjuvant, neoadjuvant), and finally therapy modality (CT, RT). When multiple patients were matched with a single patient, the patient with the closest age was chosen. Cumulative survival rates of the matched BC cases were analyzed using the KaplaneMeier (KM) estimate method. All statistical analysis was performed using R version 3.2.2 (http://www.r-project.org).
Results

Clinicopathologic Characteristics of MBC and TNBC
There were a total of 81 cases reported as MBC. Upon histologic review 28 cases were reclassified to IC-NST. We further excluded 4 cases with incomplete data and 3 cases that were stage IV disease at presentation. Therefore, the final number included in this analysis was 46. There were 17 of 46 (37%) cases with mesenchymal differentiation, 12 (26.1%) SCC, 14 (30.4%) spindle cell carcinoma, and 3 (6.5%) mixed type.
There were 37 (80.4%) cases mixed with nonmetaplastic BC (35 IC-NST and 2 lobular). Mixed MBC was seen in 3 cases; 1 mesenchymal (20%)/spindle cell (30%)/nonmetaplastic (50%); 1 SCC (60%)/spindle cell (30%)/nonmetaplastic (10%); and 1 with SCC (80%)/mesenchymal (20%; Figure 1 ). SCC was keratinizing in 4 cases and nonkeratinizing in 8 cases. Chondroid differentiation was detected in 14 cases and osteoid in 3. Table 1 shows the clinicopathologic characteristics of MBC and TNBC cases. There was no significant difference in the mean age between MBC and TNBC patients. MBC cases were more likely to present in an advanced stage (P ¼ .014). Lymph node involvement, however, was not statistically different between the 2 groups. The median tumor size was 1.7 cm (range, 0.2-13 cm) for TNBC versus 3.1 cm (range, 0.5-14 cm) for MBC (P < .001). Compared with TNBC, patients with MBC tended to more often have a mastectomy procedure (63% vs. 31%; P < .001) or CT (91% vs. 76%; P ¼ .024). However, patients with TNBC tended to receive RT more often (80% vs. 59%; P ¼ .002). The histologic subtypes of the TNBC cases were 460 (90.6%) IC-NST, 28 (5.5%) mixed IC-NST/lobular, 16 (3.1) lobular, and 4 (0.8%) apocrine.
Thirty-three of 46 (78.6%) MBC patients were treated with AC/ T (doxorubicin hydrochloride [adriamycin] and cyclophosphamide, with or without paclitaxel [taxol]) or docetaxel (taxotere). Two patients were given CMF (cyclophosphamide, methotrexate, and 5-fluorouracil). A single patient was given a sarcoma regimen of MAID (mesnex, adriamycin, ifosfamide, and dacarbazine), who developed lung metastases and died from disease 12 months after initial diagnosis. Three patients received carboplatin-based CT and 2 patients received gemcitabine-based CT. Herceptin was given as a single agent to a single patient, whereas it was given in combination with AC/T to another patient.
Estrogen receptor was positive in 4 (9%) cases, PR in 6 (13%), and HER2 in 3 (6.5%). Two cases were positive for ER as well as PR, 2 for ER but not PR, and 4 for PR but not ER. Six patients were treated with hormonal therapy, one of which was triplenegative. One of 3 patients with HER2
þ tumor was treated with trastuzumab.
Univariate and Multivariate Analyses of DFS and OS of MBC Versus TNBC
The median follow-up for MBC patients was 41 months (range, 3-168) and for TNBC patients, 67 months (range, 5-219). Disease recurrence occurred in 14 (30%) patients with MBC and 78 (15%) with TNBC (P ¼ .004). Death of disease occurred in 12 of 42 (28.6%) patients with MBC and 80 of 508 (15.7%) with TNBC (P ¼ .05). In univariate analysis, patients with MBC had worse 5-year DFS than patients with TNBC (30% vs. 89.9%; P < .001). Patients with MBC had worse 5-year OS than patients with TNBC (65.3% vs. 86.6%; P ¼ .002; Table 2 ).
In the multivariate analysis patients with MBC had almost twice (1.99; 95% confidence interval, 1.01-3.83) the risk of disease recurrence than patients with TNBC (P ¼ .05). However, there was no statistical difference between the 2 diseases in terms of OS. The other variables that had a significant effect on DFS as well as OS were T stage, lymph node status, neoadjuvant therapy, and RT. CT had only a borderline effect on DFS but not on OS (Table 3) .
Survival Results for MBC Versus Overall TNBC
Metaplastic breast carcinoma had worse DFS and OS than TNBC (P < .001 and .002, respectively; Figure 2 ). Disease recurrence occurred in 30% of MBC versus 15.5 % for TNBC patients. Death due to disease occurred in 28.6% for patients with MBC versus 15.7% for patients with TNBC.
Survival Results for Matching Group (MBC vs. TNBC)
There was almost perfect matching between MBC (n ¼ 40) and the selected TNBC cases (n ¼ 40; Table 4 ). When we performed KM curves for DFS, MBC cases had worse DFS than TNBC cases (P < .001; Figure 3A ). Disease recurrence occurred in 32.5% of MBC versus 15% for TNBC cases. Similarly, patients with MBC had worse OS than patients with TNBC (P ¼ .03; Figure 3B ). Death due to disease occurred in 30% for patients with MBC versus 15% for patients with TNBC. 
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Survival Results for MBC Subgroups
Pure MBC (n ¼ 9) cases were compared with mixed with nonmetaplastic (n ¼ 37). There was no statistical significant difference between these groups (Figure 4) . Also, the major 3 MBC groups (SCC [n ¼ 12], mesenchymal [n ¼ 17], and spindle cell [n ¼ 14]) were also compared ( Figure 5 ). There was a trend toward better local control for MBC with mesenchymal differentiation compared with SCC or spindle cell carcinoma with no statistical significance (P ¼ .32).
Discussion
Metaplastic breast carcinoma is increasingly perceived as an aggressive tumor with a poor prognosis. Several recent studies have focused on outcome in this rare and morphologically diverse malignancy. The studies, all retrospective cohorts, show conflicting results and are considerably different in design and analysis. One of the major issues in comparing survival is that MBC appears to have very different clinicopathologic parameters than other types of BC.
These include larger tumor size, higher tumor grade at presentation, negative biomarkers and lower rates of lymph node metastases. [4] [5] [6] [7] To investigate the aggressive nature of this tumor we chose to compare its clinical outcome with TNBC. We chose TNBC for 2 reasons; first, it is the most aggressive known phenotype among all other phenotypes 16 ; second, most MBC is triple negative. [4] [5] [6] [7] Comparisons between the 2 groups might be subject to bias on the basis of the differing presentations, and a matching or case control study is a reasonable way to decrease this bias. Moreover, having a relatively higher number of cases would allow performing multivariate analysis.
We reviewed the literature to explore the clinical behavior of MBC compared with TNBC. The review is summarized in Table 5 . 4, [8] [9] [10] [11] [12] [13] [14] [15] We recorded if matching was performed, the type of BC (all types combined or TNBC) that matched with MBC, the variables that the authors used to match MBC with TNBC, and finally if multivariate analysis was performed and the outcome of the multivariate analysis. There was inconsistency in data handling and SCC vs. spindle cell carcinoma). Although there was no statistical significant difference between the 3 subtypes, MBC with mesenchymal differentiation showed a trend toward better DFS than the 
pathological confounders. These findings are in part similar to the findings reported by Rakha et al, 13 who reported that MBC with mesenchymal differentiation and SCC had better outcome than spindle and mixed spindle and SCC. Luini et al studied 37 cases and matched them with TNBC cases (1 MBC to 2 TNBC) in terms of Nottingham grade, year of surgery, T stage, and N stage. They reported that patients with MBC had a hazard ratio of 5 times of dying of disease than patients with TNBC. There was no statistical significant difference between these 2 groups in terms of DFS. The limitation to this study was the lack of matching in terms of therapy modality and absence of multivariate analysis. 9 Although Jung et al performed matching as well as multivariate analyses, their study was limited by the small number of variables that were used for matching (only Grade). They reported MBC to have worse DFS and OS when the matching cohorts were compared and when multivariate analysis was performed. 4 Similarly, the study by Lee However when only patients with earlier stage (pT1-pT2) disease were considered in an attempt to further control the bias, no significant differences in the outcomes was seen between the 3 groups. The authors concluded that MBC as a group has worse prognostic variables at presentation but does not have an intrinsically worse biologic behavior than other similarly staged BC. Although this study had the largest number of cases it failed to have better matching methodology because the cases were not matched in terms of therapy and the number of cases were less than 1 to 1 (405 to 285). Moreover, the matching cases did not originate from the corresponding participating institution; instead, the authors chose to include cases from a single institution. Therefore, these results should be interpreted with caution.
In the present study, we found that the most common MBC subtype was mesenchymal differentiation 17 (37%), followed by spindle cell carcinoma 14 (30.4%), and then SCC 12 (26.1%). In our cohort, 3 (6.5%) of the cases were mixed. These frequencies vary in different studies. In the largest study by Rakha et al, 13 they
reported that the most common subtype in the Western world was spindle cell carcinoma 95 (34%) whereas SCC was the most common in the Eastern world 30 (34%). Luini et al 9 reported that MBC with mesenchymal differentiation was the most common in European patients. Zhang et al 14 reported spindle cell carcinoma 31 (34.4%) as the most common subtype in Chinese patients. This variation in frequencies might be explained by the relatively small number of cases in any series including ours, variation in tumor classification schemes, interobserver variability, and possibly different patient populations around the world. This variation might also be partly responsible for outcome differences reported in the literature. Therefore, we encourage conducting similarly designed studies from various centers around the world to enrich our literature with this relatively rare disease. We reviewed 46 cases of MBC and compared the clinicopathologic characteristics and survival data of this group with all comers of TNBC cases (n ¼ 508). We then matched (1 to 1) 40 MBC cases with 40 TNBC cases in terms of age, clinical stage, Nottingham grade, and therapy modality (CT, RT). Similar to previous findings, 4, 5, 9, 11, 12, 14 our study showed that MBC tends to present with larger tumor size and a more advanced stage. We found also that MBC had a worse DFS and OS compared with TNBC (all comers) patients (P < .001 and .002, respectively). This survival difference remained significant in our case-matched cohort (P < .001 for DFS and P ¼ .03 for OS). In the multivariate analysis, MBC had worse DFS with a hazard ratio of 1.99, whereas there was no statistical significance for OS. Our carefully matched case control study reaffirms that despite being mostly hormone receptor-negative, MBC is a distinct clinical entity from TNBC with worse long-term clinical outcomes.
There was a significant difference in our study between the treatment received by MBC patients and that received by TNBC patients. MBC patients tended to receive mastectomy and CT more often than patients with TNBC, whereas the latter had more RT (Table 1 ). This treatment difference might be a direct product of MBC presenting at a higher stage compared with TNBC. Because TNBC patients had fewer mastectomy procedures, they tended to have more RT as part of the breast-conserving surgical approach. In univariate analysis, there was a significant outcome difference with treatment modalities. Patients who underwent mastectomy, neoadjuvant therapy, or were not treated with RT all had significantly worse outcome ( Table 2 ). The difference in treatment outcomes might be because of selection bias driven by the requirement of some therapies in advanced disease stage. It is worth noting that only 3 (7.5%) MBC patients received a CT regimen that is usually not given to TNBC patients. Two patients received trastuzumab because they had positive HER2 and a single patient received a regimen usually given to sarcoma patients (MAID). It is unlikely that this difference had any effect on our matching process for 2 reasons; first, only 7.5% of the patients received a non-TNBC regimen and second, MAID therapy likely did not alter tumor behavior because the patient died of disease 12 months later. The other 2 patients who were treated with trastuzumab had 38 months and 73 months survival with no recurrence or death due to disease.
Some of the limitations of our study are the small case number (n ¼ 46) and its retrospective nature, which might introduce selection bias. In our case control matching we attempted to include factors that were significant in multivariate analysis of the 2 groups, including overall stage and treatment modality. DFS and OS were still significantly worse for MBC compared with TNBC matched cases. Moreover, we were able to perform multivariate analysis, which also showed significant correlation in DFS but not OS.
Conclusion
We conclude that MBC is an aggressive tumor that is more likely to present with worse prognostic indicators such as tumor size and stage. It is evident that more studies are needed to understand the true biologic potential of this tumor compared with other forms of BC, an endeavor that will always be challenged by the rarity of this entity. Our study adds to other studies delineating the clinicopathologic characteristics of this type of tumor, and highlights its overall worse prognosis compared with TNBC. Additional studies similar to ours are encouraged to enrich the literature about this rare entity.
Clinical Practice Points
TNBC is the most aggressive form of BC molecular subtypes. MBC is usually TN. However, the difference in outcome between this tumor and TNBC is controversial. The main reason for this controversy might be due to the criteria used for matching. Our matching criteria was very strict including all confounding variables. We found MBC to be more aggressive than TNBC.
